BMJ 2000;321:983 ( 21 October )

Papers

Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials

Michael Pignone, assistant professor of medicine, ^a Christopher Phillips, resident in preventive medicine, ^b Cynthia Mulrow, professor of medicine. ^c

^a Division of General Internal Medicine, 5039 Old Clinic Building, University of North Carolina, Chapel Hill, NC 27599-7110, USA, ^b Preventive Medicine Residency Program, University of North Carolina, Chapel Hill, ^c Division of General Internal Medicine, Audie L Murphy VA Hospital, San Antonio, TX 78284, USA

Correspondence to: M Pignone pignone{at}med.unc.edu

Objective: To summarise the effect of primary prevention with lipid lowering drugs on coronary heart disease events, coronary heart disease mortality, and all cause mortality.
Design: Meta-analysis.
Identification: Systematic search of the Medline database from January 1994 to June 1999 for English language studies examining drug treatment for lipid disorders (use of the MeSH terms "hyperlipidemia" and "anticholesteremic agents," keyword searches for individual drug names, and a search strategy for identifying randomised trials to capture relevant articles); identification of older studies through systematic reviews and hand search of bibliographies.
Inclusion criteria: All randomised trials of at least one year's duration that examined drug treatment for patients with no known coronary heart disease, cerebrovascular disease, or peripheral vascular disease and that measured clinical end points, including all cause mortality, coronary heart disease mortality, and non-fatal myocardial infarctions.
Data extraction: Review of the articles and extracted relevant data by two authors separately, with disagreements resolved by consensus.
Results: Four studies met eligibility criteria. Drug treatment reduced the odds of a coronary heart disease event by 30% (summary odds ratio 0.70, 95% confidence interval 0.62 to 0.79) but not the odds of all cause mortality (0.94, 0.81 to 1.09). When statin drugs were considered alone, no substantial differences in results were found.
Conclusions: Treatment with lipid lowering drugs lasting five to seven years reduces coronary heart disease events but not all cause mortality in people with no known cardiovascular disease.

---

© BMJ 2000
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

Innovation
BMJ 2000 321: 0. [Full Text] [PDF]

Innovation
BMJ 2000 321: 0. [Full Text] [PDF]

Lipid lowering for heart attack works best in those at high risk
BMJ 2000 321: 0. [Full Text]

Statins: underused by those who would benefit

Stephen B Hulley, Deborah Grady, and Warren S Browner
BMJ 2000 321: 971-972. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Young, R P, Hopkins, R, Eaton, T E (2009). Potential benefits of statins on morbidity and mortality in chronic obstructive pulmonary disease: a review of the evidence. Postgrad. Med. J. 85: 414-421 [Abstract] [Full text]  
• Dadlani, H., Ballinger, M. L., Osman, N., Getachew, R., Little, P. J. (2008). Smad and p38 MAP Kinase-mediated Signaling of Proteoglycan Synthesis in Vascular Smooth Muscle. J. Biol. Chem. 283: 7844-7852 [Abstract] [Full text]  
• Young, R. P., Hopkins, R., Eaton, T. E. (2007). Forced expiratory volume in one second: not just a lung function test but a marker of premature death from all causes. Eur Respir J 30: 616-622 [Abstract] [Full text]  
• Fidan, D., Unal, B., Critchley, J., Capewell, S. (2007). Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000-2010. QJM 100: 277-289 [Abstract] [Full text]  
• Penning-van Beest, F. J.A., Termorshuizen, F., Goettsch, W. G., Klungel, O. H., Kastelein, J. J.P., Herings, R. M.C. (2007). Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. Eur Heart J 28: 154-159 [Abstract] [Full text]  
• Marrugat, J., Subirana, I., Comin, E., Cabezas, C., Vila, J., Elosua, R., Nam, B.-H., Ramos, R., Sala, J., Solanas, P., Cordon, F., Gene-Badia, J., D'Agostino, R. B, for the VERIFICA (Validez de la Ecuacion de Riesgo, (2007). Validity of an adaptation of the Framingham cardiovascular risk function: the VERIFICA study. J. Epidemiol. Community Health 61: 40-47 [Abstract] [Full text]  
• Thavendiranathan, P., Bagai, A., Brookhart, M. A., Choudhry, N. K. (2006). Primary Prevention of Cardiovascular Diseases With Statin Therapy: A Meta-analysis of Randomized Controlled Trials. Arch Intern Med 166: 2307-2313 [Abstract] [Full text]  
• Go, A. S., Lee, W. Y., Yang, J., Lo, J. C., Gurwitz, J. H. (2006). Statin therapy and risks for death and hospitalization in chronic heart failure.. JAMA 296: 2105-2111 [Abstract] [Full text]  
• Pignone, M. (2006). Cost-Effectiveness of Statins Added to Aspirin Therapy.. ANN INTERN MED 145: 233-234 [Full text]  
• Pignone, M., Earnshaw, S., Tice, J. A., Pletcher, M. J. (2006). Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis.. ANN INTERN MED 144: 326-336 [Abstract] [Full text]  
• Eliassen, A. H., Colditz, G. A., Rosner, B., Willett, W. C., Hankinson, S. E. (2005). Serum Lipids, Lipid-Lowering Drugs, and the Risk of Breast Cancer. Arch Intern Med 165: 2264-2271 [Abstract] [Full text]  
• Chapman, R. H., Benner, J. S., Petrilla, A. A., Tierce, J. C., Collins, S. R., Battleman, D. S., Schwartz, J. S. (2005). Predictors of Adherence With Antihypertensive and Lipid-Lowering Therapy. Arch Intern Med 165: 1147-1152 [Abstract] [Full text]  
• Mantel-Teeuwisse, A K, Goettsch, W G, Klungel, O H, de Boer, A, Herings, R M C (2004). Long term persistence with statin treatment in daily medical practice. Heart 90: 1065-1066 [Full text]  
• Walsh, J. M. E., Pignone, M. (2004). Drug Treatment of Hyperlipidemia in Women. JAMA 291: 2243-2252 [Abstract] [Full text]  
• Raithatha, N., Smith, R. D (2004). Paying for statins. BMJ 328: 400-402 [Full text]  
• Critchley, J. A., Capewell, S. (2003). Mortality Risk Reduction Associated With Smoking Cessation in Patients With Coronary Heart Disease: A Systematic Review. JAMA 290: 86-97 [Abstract] [Full text]  
• Law, M R, Wald, N J, Rudnicka, A R (2003). Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 326: 1423- [Abstract] [Full text]  
• Akosah, K. O., Schaper, A., Cogbill, C., Schoenfeld, P. (2003). Preventing myocardial infarction in the young adult in the first place: how do the national cholesterol education panel iii guidelines perform?. J Am Coll Cardiol 41: 1475-1479 [Abstract] [Full text]  
• Mintzes, B. (2002). For and against: Direct to consumer advertising is medicalising normal human experience: For. BMJ 324: 908-909 [Full text]  
• Peeters, A, Mamun, A.A, Willekens, F, Bonneux, L (2002). A cardiovascular life history. Eur Heart J 23: 458-466 [Abstract] [Full text]  
• Kreisberg, R. A., Oberman, A. (2002). Lipids and Atherosclerosis: Lessons Learned from Randomized Controlled Trials of Lipid Lowering and Other Relevant Studies. J. Clin. Endocrinol. Metab. 87: 423-437 [Full text]  
• O'Hare, A., Johansen, K. (2001). Lower-Extremity Peripheral Arterial Disease among Patients with End-Stage Renal Disease. J. Am. Soc. Nephrol. 12: 2838-2847 [Abstract] [Full text]  
• Hall, N. F, Gale, C. R, Syddall, H., Phillips, D. I W, Martyn, C. N (2001). Risk of macular degeneration in users of statins: cross sectional study. BMJ 323: 375-376 [Full text]  
• Havranek, E. P (2001). Review: lipid lowering drugs decrease coronary artery disease (CAD) events but not all cause or CAD mortality in men with no history of CAD. Evid. Based Med. 6: 85-85 [Full text]  
• (2001). Lipid-Lowering Drugs in Primary Prevention of CHD: An Updated Meta-Analysis. Journal Watch Cardiology 2001: 3-3 [Full text]  
• Jordan, V. C. (2001). Estrogen, Selective Estrogen Receptor Modulation, and Coronary Heart Disease: Something or Nothing. JNCI J Natl Cancer Inst 93: 2-4 [Full text]  
• (2000). Lipid Lowering for Primary Prevention: Still Not for Everyone. JWatch General 2000: 1-1 [Full text]  
• Hulley, S. B, Grady, D., Browner, W. S (2000). Statins: underused by those who would benefit. BMJ 321: 971-972 [Full text]  

Rapid Responses:

Read all Rapid Responses

Correct data, incorrect conclusion

H T Ong
bmj.com, 28 Oct 2000 [Full text]

Southern European countries and primary prevention of coronary heart disease

Eduard Diogène
bmj.com, 28 Oct 2000 [Full text]

Non-cardiac mortality and cholesterol lowering drugs

Christopher Cates
bmj.com, 29 Oct 2000 [Full text]

Correction: Drug Dosage

Etzel Gysling
bmj.com, 11 Nov 2000 [Full text]

Absolute benefit vs Relative risk

V Baskar, et al.
bmj.com, 29 Nov 2000 [Full text]

lipids-lowering and statins

S Sethi
bmj.com, 1 Dec 2000 [Full text]

Incorrect data in study by Pignone

Robert M Ewart
bmj.com, 15 Dec 2000 [Full text]

Initial Cholesterol Levels and Reduction of Ischemic Cardiopathy with Lipid Lowering Drugs

V Ruiz-Garcia
bmj.com, 26 Apr 2001 [Full text]

Reply to Dr Ewart

Michael Pignone, et al.
bmj.com, 9 Mar 2001 [Full text]

Issues in meta-analysis raised by Pignone

Robert Ewart
bmj.com, 8 May 2001 [Full text]

UPDATE: Statins Lack Mortality Benefit

Eddie Vos, et al.
bmj.com, 22 Jan 2003 [Full text]

Re: update on statins and mortality

Richard G Fiddian-Green
bmj.com, 23 Jan 2003 [Full text]

Self-citation rates for electronic responses

Anthony R Cox
bmj.com, 25 Jan 2003 [Full text]

Re: Self-citation rates for electronic responses

John Nottingham
bmj.com, 5 Mar 2003 [Full text]

Narcissus syndrome?

Richard G Fiddian-Green
bmj.com, 6 Mar 2003 [Full text]

Re: Narcissus syndrome?

John Nottingham
bmj.com, 7 Mar 2003 [Full text]

Might statins cause myocyte apoptosis by activating endonuclease?

Richard G Fiddian-Green
bmj.com, 20 Aug 2003 [Full text]

Online poll

Find out more >>